Plain-English translation of NCT05918029 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether potassium citrate, a supplement form of potassium, can help protect bones in people with chronic kidney disease. People with kidney disease often lose bone strength and have more fractures, but there aren't many proven, safe treatments available across different ages. This study will help researchers understand if this medication could be a safe way to help protect bones in both children and adults with kidney disease.
People with chronic kidney disease experience significant bone loss and fractures throughout their lives, but doctors don't have many proven and safe options to prevent this. This research aims to see if this treatment could fill that gap and become a protective therapy that works for both children and adults.
You would be randomly assigned to take either potassium citrate tablets (or liquid solution if you're a child who can't swallow pills) or an identical-looking placebo twice daily for the duration of the study. Researchers will monitor your bone health, kidney function, and blood potassium levels through regular visits and blood tests. This is a blinded study, meaning neither you nor the study team will know which treatment you're receiving until the study ends, ensuring fair and objective results.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States